With a team of experienced executives and renowned scientists from top academic institutions, including Harvard and the University of New South Wales, Proto Axiom aims to bring world-class pre-clinical and discovery expertise to Australia. By centralizing and incubating pre-clinical assets, the firm bridges the gap in domestic expertise and enables the successful commercialization of Australia's scientific intellectual property. Founded in 2021, Proto Axiom addresses the lack of early-stage venture capital funds in Australia's biotech sector, supporting the development and commercialization of groundbreaking science.